Welcome to our dedicated page for Cbd Life Science news (Ticker: CBDL), a resource for investors and traders seeking the latest updates and insights on Cbd Life Science stock.
CBD Life Sciences Inc. (CBDL) is a publicly traded wellness company active in the CBD, hemp, cannabis, functional mushroom, and nutraceutical sectors through its flagship brand The CBD Vault. The CBDL news feed on Stock Titan aggregates company-issued updates and announcements that describe how the business is expanding its product portfolio and distribution footprint.
In its recent news, CBD Life Sciences highlights agreements with dispensaries, luxury spas, and wellness retailers, including partnerships with Smoking Scholars in the Bronx, Red Hots Spa locations in New York, and Mother Earth Juice Bar at John F. Kennedy International Airport. These items outline how CBDL places CBD topicals, infused beverages, hemp-derived pain creams, and other wellness products into high-traffic consumer environments.
Press releases also cover product launches such as anti-inflammatory gels, CBD beverages, functional mushroom offerings, and plant-based energy and diet gummies. The company’s communications describe participation in cannabis conferences, Letters of Intent with dispensaries, and efforts to grow wholesale and retail channels in markets like New York and New Jersey.
Investors and followers can use this news page to review CBDL’s own descriptions of its partnerships, product introductions, and channel development over time. By reading these updates together, readers can see how CBD Life Sciences Inc. presents its strategy in CBD wellness, cannabis-related products, functional beverages, and mushroom-based formulations under The CBD Vault brand.
CBD Life Sciences Inc. (OTC PINK:CBDL), operating through its subsidiary The CBD Vault Inc., has announced a significant rebranding from LBC Bioscience Inc. to better reflect its commitment to innovation in the CBD market.
The CBD Vault now offers over 60 premium products, including pain creams, roll-ons, Delta-8 & Delta-10 gummies and cartridges, and Kava and Kratom beverages. The company aims to enhance its marketing efforts by hiring specialists in CBD marketing and advertising.
Additionally, CBD Life Sciences is exploring opportunities to acquire a marijuana dispensary and additional retail locations to diversify its market presence. The company is focused on leveraging the growing CBD market to deliver shareholder value.
CEO Lisa Nelson thanked consumers and shareholders for their support and highlighted the company's strategic steps towards growth and success.
Summary not available.
CBD Life Sciences (OTC PINK:CBDL) has announced a strategic partnership with Sunset Wholesale West, Arizona's largest wholesaler, through its subsidiary, LBC Bioscience Inc.. This alliance positions LBC to distribute its Elev8 gummies in large quantities, enhancing visibility across over 14,000 retailers, including dispensaries and smoke shops. CEO Lisa Nelson highlighted the potential for significant revenue growth and market expansion. The company aims to provide high-quality, affordable CBD products in 2023, continuing to address various health issues associated with CBD consumption.
CBD Life Sciences (CBDL) is launching a same day home delivery service for its CBD products across the Phoenix-Scottsdale Metro Area. This initiative, announced through its subsidiary LBC Bioscience Inc., aims to enhance convenience for local customers, especially the elderly. Orders can be placed via phone or online at www.lbcbioscienceinc.com. The company is also expanding its product offerings with a 2023 Mass Distributor Wholesale Catalog. All products are THC-free and undergo rigorous third-party lab testing. CBDL aims to improve customer accessibility and quality of life with its premium products.
CBD Life Sciences (OTC PINK: CBDL) announced the launch of a new CBD Oil infused with high-quality terpenes via its subsidiary, LBC Bioscience Inc.. The oil, available in strengths of 500MG, 1500MG, and 3000MG, will be sold online in 14 flavors. This product claims to have rapid absorption and is four times more potent than standard hemp-derived tinctures. The company has established a new manufacturing facility and anticipates increased revenue as it expands its product line. CBD's benefits extend to various health conditions, enhancing its market appeal.
CBD Life Sciences (OTC PINK: CBDL) has launched new Delta-8 gummies through its subsidiary, LBC Bioscience Inc.. Each gummy contains 100MG of Delta-8 THC, with a total of 2000MG per jar. The product employs a 2:1 blend of CBD and Delta-8, promoting a calming yet focused experience. The gummies will be available in-store and online shortly. The company emphasizes thorough testing for consistency and quality, supporting various health benefits associated with CBD, including pain management and neurological support.
CBD Life Sciences (OTC PINK:CBDL) announced a landmark event with the passage of the H.R. 8454 - Medical Marijuana and Cannabidiol Research Expansion Act, signed by both the U.S. House and Senate. This historic legislation creates a new framework for marijuana research, allowing registered entities to manufacture and distribute marijuana for medical purposes. CEO Lisa Nelson emphasized that this opens numerous opportunities as the perception of marijuana and CBD evolves. The bill aims to streamline research processes and remove barriers, promoting the benefits of CBD for various medical conditions.
CBD Life Sciences (OTC PINK:CBDL) announces the launch of its new product, PR-X 100MG tablets, designed to support prostate health, urinary, and hair needs. The product features natural ingredients combined with high-quality Full-Spectrum CBD Isolate, and has undergone lab testing for potency. CEO Lisa Nelson highlights this launch as a significant step for the company, aimed at driving revenue growth and expanding market reach in Arizona. The press release also notes the extensive benefits of CBD for various health conditions.
CBD Life Sciences (OTC PINK: CBDL) announces the launch of a Mobile CBD Store on Wheels, developed through its subsidiary, LBC Bioscience Inc.
This initiative aims to enhance revenue and growth by allowing the company to sell CBD products at various events across the U.S. The mobile store will offer popular items like pre-rolls, edibles, and CBD beverages. The food truck industry has seen an impressive growth rate of 12.1% annually, indicating strong potential for success in this venture. LBC Bioscience plans to keep shareholders updated on developments.
CBD Life Sciences (OTC PINK:CBDL) is set to launch a novel bladder control supplement via its subsidiary, LBC Bioscience Inc.. This all-natural product will be infused with CBD and aims to aid sleep, relieve stress, and control bladder function. The global cannabidiol market is projected to grow significantly from USD 3,675.1 million in 2022 to USD 55,791.3 million in 2028 at a CAGR of 47.49%. The company remains committed to keeping the public updated as research progresses on this innovative product.